CAJ | 학술논문

手术切除和肝移植仍然是肝细胞癌(HCC)的治疗首选.对于不适宜手术切除的晚期HCC,传统的化疗并不能改善患者的预后.分子靶向药物的出现为晚期HCC的治疗提供了新的治疗手段.多靶点抑制剂、血管内皮生长抑制剂、单克隆抗体等分子靶向药物已经在HCC中广泛研究和应用.
수술절제화간이식잉연시간세포암(HCC)적치료수선.대우불괄의수술절제적만기HCC,전통적화료병불능개선환자적예후.분자파향약물적출현위만기HCC적치료제공료신적치료수단.다파점억제제、혈관내피생장억제제、단극륭항체등분자파향약물이경재HCC중엄범연구화응용.
Surgical resection and liver transplantation are still the preferred treatments for patients with hepatocellular carcinoma (HCC).For the patients with advanced HCC which are not suitable for surgical resection,traditional chemotherapy can not improve the prognosis.Molecular targeted therapy is a new method and tendency in the treatment of HCC.Multiple targets inhibitors,vascular endothelial growth factor inhibitors and monoclonal antibodies for HCC are widely researched and applied.